Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has granted patent no. 8,022,279 to a US based developer of cancer therapies, Celator Pharmaceuticals.
Subscribe to our email newsletter
The US patent no. 8,022,279 includes the key composition features of CPX-351, a liposome formulation that co-encapsulates cytarabine and daunorubicin at a synergistic 5:1 molar ratio.
Additionally, the company has also received two patents from the Japanese Patent Office.
The Japanese patent covers CombiPlex method of developing drug combinations as well as the company’s metal-based drug loading technology.
Celator CEO Scott Jackson said the positive results for CPX-351 in a previously reported Phase 2 clinical trial have supported the planning for a pivotal Phase 3 registration trial.
"With the Patent Term Adjustment, the US patent provides protection until September 2027 which, should we be successful in gaining regulatory approval, significantly extends," Jackson said.